Posts tagged Clinical
Lilly Halts Development of Semagacestat for Alzheimer’s Disease Based on Preliminary Results of Phase III Clinical …
Aug 17th
Lilly Halts Development of Semagacestat for Alzheimer’s Disease Based on Preliminary Results of Phase III Clinical …
Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer’s disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.
Read more on PR Newswire via Yahoo! Finance
Fibrocell Science, Inc. Submits Clinical Study Report (CSR) to U.S. Food & Drug Administration for Phase II/III Trial …
Aug 14th
Fibrocell Science, Inc. Submits Clinical Study Report (CSR) to U.S. Food & Drug Administration for Phase II/III Trial …
EXTON, Pa., Aug. 9 /PRNewswire-FirstCall/ — Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted a clinical study report for its Phase II/III study of azficel-T for the treatment of moderate to severe acne scars to the U.S. Food …
Read more on redOrbit
News From The Journal Of Clinical Investigation: July 26, 2010
Jul 28th
News From The Journal Of Clinical Investigation: July 26, 2010
CARDIOVASCULAR DISEASE: Flushing out key limitations to a drug that protects against heart attack The drug niacin is used to modulate fat levels in the blood and thereby reduce the risk of a heart attack. However, noxious effects on the skin that have been termed ‘flushing’ limit its use in the clinic. Understanding the mechanisms underlying flushing might identify therapeutic targets that could …
Read more on Medical News Today
Recent Comments